Perrigo Company PLC (PRGO)vsTeva Pharma Industries Ltd ADR (TEVA)
PRGO
Perrigo Company PLC
$9.69
+0.52%
HEALTHCARE · Cap: $1.27B
TEVA
Teva Pharma Industries Ltd ADR
$29.46
+1.10%
HEALTHCARE · Cap: $33.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 306% more annual revenue ($17.26B vs $4.25B). TEVA leads profitability with a 8.2% profit margin vs -33.5%. PRGO appears more attractively valued with a PEG of 1.14. TEVA earns a higher WallStSmart Score of 73/100 (B).
PRGO
Hold48
out of 100
Grade: D+
TEVA
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for PRGO.
Margin of Safety
+39.4%
Fair Value
$56.63
Current Price
$29.46
$27.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.3%
Earnings expanding 40.0% YoY
Generating 1.0B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -38.7% — below average capital efficiency
Revenue declined 2.5%
Earnings declined 63.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : PRGO
The strongest argument for PRGO centers on Price/Book. PEG of 1.14 suggests the stock is reasonably priced for its growth.
Bull Case : TEVA
The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bear Case : PRGO
The primary concerns for PRGO are Market Cap, Return on Equity, Revenue Growth.
Bear Case : TEVA
The primary concerns for TEVA are Altman Z-Score.
Key Dynamics to Monitor
PRGO profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.
TEVA carries more volatility with a beta of 0.72 — expect wider price swings.
TEVA is growing revenue faster at 11.4% — sustainability is the question.
TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (73/100 vs 48/100) and 11.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Perrigo Company PLC
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Perrigo Company plc is an American Irish registered manufacturer of private label over-the-counter pharmaceuticals.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?